公司资料
GRI Bio 股价、新闻与催化剂
- 股票代码:
- GRI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.73 USD (+3.59%)
收盘价
最后更新: 2026年8月17日
3.56M USD
市值
股价为何变动
As of Aug 17, 2026, GRI closed up 3.59% at $1.73. No new same-company headline was identified in the current news window.
公司概览
业务概览
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
所在地与行业分类
GRI is a U.S.-listed biotech entry with a small-cap development profile. It sits in biotechnology rather than medtech or services.
商业模式特征
The business depended on early scientific progress, platform credibility, and access to capital. Investors historically watched whether the company could focus its pipeline and keep programs alive.
生物医药行业定位
GRI occupies the historical small-cap biotech bucket. It is the type of name where the market cared most about whether the science could survive the financing cycle.
未来催化剂
- GRI Bio's catalyst setup now looks most tied to cough/shortness of breath, Commission, and the rest of its current pipeline. What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis.... That setup makes the next update more important than the headline financials themselves. The partnership angle also matters here, especially around (6) the inability of the Company to identify, in-license or acquire additional technology.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。